Reblozyl (luspatercept or luspatercept-aamt) is an injectable medication used to treat anemia (low red blood cells) in adults with beta thalassemia or certain myelodysplastic syndromes (MDS) who require regular red blood cell transfusions. Reblozyl (luspatercept) is given by a healthcare provider every 3 weeks.
Anemia in adults with beta thalassemia who require regular red blood cell (RBC) transfusions
Anemia in adults with myelodysplastic syndromes with ring sideroblasts (MDS-RS) or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) who can't receive an erythropoiesis stimulating agent (ESA) and need regular RBC transfusion
Reblozyl (luspatercept) is a biologic called an erythroid maturation agent. It helps immature red blood cells develop and work properly. By raising the amount of healthy red blood cells, Reblozyl (luspatercept) can treat your anemia.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Treatment is every 3 weeks
Can lower the need for RBC transfusions
Dose is individualized for each person
Not approved for children
Has to be given by injection
Can't give yourself the injection; must be given by a provider
You will get regular blood tests throughout your treatment with Reblozyl (luspatercept). Your provider will monitor your hemoglobin to see if your anemia is getting better.
Remember to go to all of your treatment appointments to make sure you get your injections on time.
It's also important to get all of your labs done so your provider can adjust your dose properly.
Let your provider know if you're pregnant or planning to become pregnant before starting Reblozyl (luspatercept). Since this medication can cause harm to your unborn baby, speak with your provider for a safer medication.
If you're a female who's able to have a baby, your provider will have you take a pregnancy test before starting Reblozyl (luspatercept). Take birth control during treatment and for 3 months after the last dose to prevent pregnancy.
It's possible for Reblozyl (luspatercept) to pass into your breast milk and cause harm to your baby. Don't breastfeed during your treatment and for 3 months after the last dose.
Reblozyl (luspatercept) might make it harder to become pregnant if you're a female, so let your provider know if this is a concern for you.
Reblozyl (luspatercept) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Risk factors: Spleen removal | Taking hormone replacement therapy | Taking birth control | Smoking
Some people with beta thalassemia have experienced a blood clot while taking Reblozyl (luspatercept). Speak with your provider before starting this medication if you have a history of blood clots or have any of the risk factors listed above. Your provider can give you medications to lower your risk of blood clots, or find a different medication that's safer for you. Get medical help right away if you experience signs of a blood clot, such as chest pain, leg pain, trouble breathing, sudden numbness or weakness on one side of the body, severe headache or confusion, or trouble speaking or walking.
Reblozyl (luspatercept) can raise your blood pressure. There's a risk of developing high blood pressure or a worsening of your condition if you currently have high blood pressure. Discuss with your provider to see if you need blood pressure medications or if you need adjustments to your current medications.
Reblozyl (luspatercept) might cause harm to your unborn baby if you're getting this medication during pregnancy. If you're a female who can have a baby, use an effective form of birth control during your treatment with Reblozyl (luspatercept) and for at least 3 months after the last dose. Let your provider know right away if you become pregnant or think that you might be pregnant during your treatment.
You provider will determine your dose based on your body weight. The typical starting dose is 1 mg/kg of body weight injected subcutaneously (under the skin) once every 3 weeks. Your provider will adjust your dose based on your response to the medication. Injections are given by your healthcare provider.
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.